Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders
Agreement enables sustainable patient access of the only EU-approved treatment for myotonia symptoms
in non-dystrophic myotonic disorders
Mumbai, Zug, January 9, 2023: Global pharma major Lupin Limited (Lupin) and Exeltis Healthcare S.L (Exeltis) announced today that the…